Lack of an Association Between a Rs9818870 Marker at the Mras Gene Locus and Acute Coronary Syndrome in Czech Males

Abstract

Acute coronary syndrome (ACS) including myocardial infarction is one of the leading and preventable causes of death in industrialized countries. Conventional cardiovascular risk factors are responsible for approximately 50% of cases. Attention is therefore focused also on genetic variants that are not strongly associated with conventional risk factors. One of them is the rs9818870 marker within the MRAS gene (muscle RAS oncogen homolog-gene, OMIM 608435, 3q22.3), which was recognized as a risk factor for cardiovascular events in Western populations. We analyzed the relationship between the rs9818870 variant and the risk of ACS in the Czech population. Methods: Rs9818870 (C→T) variant was successfully analyzed by PCR-RFLP at the 1,122 control males, younger than 65 years (post- MONICA study) and 1,190 males, consecutive patients with ACS (younger than 65 years). ANOVA and chisquare were used for statistical analyses. Results: Rs9818870 polymorphism was not associated with conventional risk factors (plasma lipids, blood pressure, obesity, smoking, diabetes mellitus) in the control group. We have not detected any association between the DNA marker and ACS (controls – CC = 70.8%, CT = 26.4%, TT = 2.8% vs. patients – CC = 69.7%, CT= 28.2%, TT= 2.1%; P = 0.34). Conclusion: Rs9818870 variant within the MRAS gene region is not robust risk factor for ACS development in the Czech Slavonic males.Acute coronary syndrome (ACS) including myocardial infarction is one of the leading and preventable causes of death in industrialized countries. Conventional cardiovascular risk factors are responsible for approximately 50% of cases. Attention is therefore focused also on genetic variants that are not strongly associated with conventional risk factors. One of them is the rs9818870 marker within the MRAS gene (muscle RAS oncogen homolog-gene, OMIM 608435, 3q22.3), which was recognized as a risk factor for cardiovascular events in Western populations. We analyzed the relationship between the rs9818870 variant and the risk of ACS in the Czech population. Methods: Rs9818870 (C→T) variant was successfully analyzed by PCR-RFLP at the 1,122 control males, younger than 65 years (post- MONICA study) and 1,190 males, consecutive patients with ACS (younger than 65 years). ANOVA and chisquare were used for statistical analyses. Results: Rs9818870 polymorphism was not associated with conventional risk factors (plasma lipids, blood pressure, obesity, smoking, diabetes mellitus) in the control group. We have not detected any association between the DNA marker and ACS (controls – CC = 70.8%, CT = 26.4%, TT = 2.8% vs. patients – CC = 69.7%, CT= 28.2%, TT= 2.1%; P = 0.34). Conclusion: Rs9818870 variant within the MRAS gene region is not robust risk factor for ACS development in the Czech Slavonic males.